Clinical Trial Update: Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel plus immunotherapy before prostatectomy in high-risk prostate cancer was terminated. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Benaroya Research Institute | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-01-20